Christopher John Stanley

This inventor holds 24 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents, primarily in Nucleic Acid Technologies. Top assignees: Scientific Generics Limited, Affymetrix, Inc., Torsana Diabetes Diagnostics A/s. Active years: 1992-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher John Stanley. Retrieved from https://idiyas.com/inventor/christopher-john-stanley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24

% Patents Active = 83.3

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 1.6

ph-index = 12

Forward Citations = 652(Granted Patents)

Location History:

St. Ives, GB (1996 - 1998)
Cambridgeshire, GB (1992 - 2003)
Woodhurst, GB (2001 - 2010)
Huntingdon, GB (1998 - 2013)
London, GB (2013)
Cambridge, GB (2013 - 2014)

Company Filing History:

5 out of 29

Scientific Generics Limited

Torsana Diabetes Diagnostics A/s

Microsens Biophage Limited

Boehringer Mannheim Gmbh

Microsens Biphage Limited

patent

10. 1 out of 2

Microsens Medtech Limited

patents

11. 1 out of 1

Oakville Trading Hong Kong Limited

Years Active: 1992-2014

Loading Chart...

Areas of Expertise:

Protein Aggregation

Electrochemical Denaturation

Nucleic Acid Analog

Optical Sensor

Micro-organisms

Prion Proteins

Carrier Macromolecules

Analytical Determinations

Chelating Functionality

Solid-phase Capture

In Situ Measurement

Multivalent Inorganic Cations

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8658374 - Binding of aggregated forms of proteins (2014-02-25),

2. 8603771 - Capture of micro-organisms (2013-12-10),

3. 8460885 - Binding of pathological forms of prion proteins (2013-06-11),

4. 8383617 - Treatment of protein aggregation diseases (2013-02-26),

5. 7659076 - Binding of pathological forms of prion proteins (2010-02-09),

6. 7279311 - Use of nucleic acids bound to carrier macromolecules (2007-10-09),

7. RE38525 - Optical sensor for in situ measurement of analytes (2004-06-08),

8. 6627460 - Method for preparing water-soluble cross-linked conjugates (2003-09-30),

9. 6625479 - Optical sensor for in situ measurement of analytes (2003-09-23),

10. 6613527 - Electrochemical denaturation of double-stranded nucleic acid (2003-09-02),

11. 6395489 - Electrochemical denaturation of double-stranded nucleic acid (2002-05-28),

12. 6365400 - Electrochemical denaturation of double-stranded nucleic acid (2002-04-02),

13. 6346378 - Nucleic acid analogs with a chelating functionality (2002-02-12),

14. 6207385 - Use of nucleic acids bound to carrier macromolecules (2001-03-27),

15. 6197508 - Electrochemical denaturation and annealing of nucleic acid (2001-03-06),

Certainly! Here is the article based on the information provided:

Title: Unveiling the Innovations of Christopher John Stanley in the Field of Biotechnology

Introduction:

Christopher John Stanley, a renowned inventor hailing from Huntingdon, GB, has left a remarkable footprint in the realm of biotechnology with his inventive patents and groundbreaking work.

Latest Patents:

Among his impressive portfolio of 24 patents, one notable creation is the "Binding of aggregated forms of proteins" patent. This innovation focuses on selectively binding aggregating proteins, such as IgG, using polyionic binding agents like dextran sulphate or pentosan under specific conditions for accurate assays. Another notable patent is "Capture of micro-organisms," which involves capturing micro-organisms present in aqueous liquids on solid surfaces using water-soluble polymers like polyethyleneglycol or polyvinylpyrrolidone.

Career Highlights:

Throughout his career, Christopher John Stanley has significantly contributed to companies like Scientific Generics Limited and Affymetrix, Inc., where his expertise and inventive spirit have paved the way for groundbreaking advancements in biotechnology.

Collaborations:

Collaborating with talented individuals like Stuart Mark Wilson and Anders Weber, Christopher John Stanley has synergized his creative vision with their expertise to bring forth innovative solutions in the field of biotechnology.

Conclusion:

In conclusion, Christopher John Stanley's inventive prowess and dedication to pushing the boundaries of biotechnology have undeniably made a lasting impact in the industry. His patents stand as a testament to his innovative spirit and commitment to advancing scientific knowledge and capabilities.

If you have any further questions or need more information, feel free to ask!

Profile summary based on public USPTO records.